Navigation Links
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Date:1/13/2009

rofiles, with no unexpected toxicities. There was a lower incidence of grade 3/4 adverse events (AEs) and hematologic AEs in the pooled XELOX group compared to the FOLFOX-4 group. Grade 3/4 gastrointestinal disorders and hand-foot syndrome were more common with XELOX compared to FOLFOX-4.

Results regarding overall survival in addition to progression-free survival were previously presented at ASCO GI in 2007. These 14-month follow-up data result from the overall survival analysis and include all patients involved in the trial (pooled XELOX-containing arms vs. pooled FOLFOX-4-containing arms).

About XELOX

XELOX is an abbreviation for a type of combination chemotherapy used to treat colorectal cancer; it contains Xeloda (capecitabine) plus oxaliplatin.

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
8. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Facet Solutions, Inc. today announced that it has...trolled ACADIA(TM) IDE study for lumbar spinal ste...009," stated President and CEO, Geoff Pardo. "It i...omes that surgeons are seeing, and the ease with w...on people are diagnosed with lumbar spinal stenosi...
(Date:11/9/2009).... 9 Hill-Rom (NYSE: H...tion of a joint venture that will focus on the sal...face replacement systems that are intended to be s...for surfaces that are technologically obsolete or ...al leader in patient support systems and related t...
(Date:11/9/2009)...e/ -- Momentum is building for the early December...ond P-MEC India pharma ingredients, services and t...exhibitors from over 80 countries are expected...ts, being held on 1 - 3 December. ,, In additi...lude two new launches. BioPh India will focus on...
Breaking Medicine Technology:Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study 2Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Forecast Looks Good for India Pharma Shows 2Forecast Looks Good for India Pharma Shows 3While you were sleeping 47771 1While you were sleeping 47771 2Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 1Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 2ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 1ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 2
...R-132 could provide a new therapeutic approach for...er, QUEBEC CITY, April 17, 2007 /PRNewswire-FirstC... biopharmaceutical company,focused on endocrine th...tlining in vivo data for its growth hormone-releas...ncer, at the American,Association for Cancer Resea...
...As previously announced, primary endpoint not met;...study treatment with ERBITUX,-, NEW YORK, April 16...ncorporated and Bristol-Myers Squibb Company today...a randomized,open-label, multi-center Phase III t...tecan to irinotecan alone in patients with,metasta...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
(Date:11/9/2009)...inds differences in mood despite similar weight lo...- Both a high-fat, low-carbohydrate diet such as t... diet appear to help people lose pounds over the c...ow-fat diets will result in long-term improvement ...of Archives of Internal Medicine . , People on...
(Date:11/9/2009)... Fast food chains are often blamed for the inc...by Fitness.com.au however finds that 80% of people...lity. , (PRWEB) November ...deo games were behind Australia’s obesity ep...st innocent bystanders. A recent survey commission...
(Date:11/9/2009)...mprehensive Cancer Network (NCCN) has posted a dra...raft paradigm for near-term comparative effectiven... The document introduces the NCCN Comparative Ther... that compares the risk-versus-benefit of differen...al Practice Guidelines in Oncology(TM). The paper ...
(Date:11/9/2009)... Highlighting a commitment to prov...ced entertainment and digital display technology o...ng-Term Care and Hospital Grade LCD HDTVs this wee... Aging 2009 annual meeting and exposition (booth #...e of "HealthView(TM)" Long-Term Care LCD HDTVs bri...
(Date:11/9/2009)...uestion of why this is so, however , ,...tomy, women with very dense breasts have a higher ...a new study shows. , Breast density has already...breast cancer, and experts have suspected that ver...reased risk of cancer recurrence at the site of th...
Breaking Medicine News(10 mins):Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3
..., Despite the commitments...lized training and practicing medicine in fields o... Honors College at Indiana University of Pennsylva...tients with different needs to Rebecca Pounds, who...
..., Chief Medical Officer, ... 2nd Annual Public Healthcare congress in Washingt...resentation, "Lessons Learned; Implementing a...ciency and security of patient information exchang...
..., Medical and nursing scr...ly redesigned site. With new products added and a ...ecoming the leading destination for hospital unifo...s new user friendly website. The new site has impl...
..., INDIANAPOLIS Public health professionals from...ianapolis for a national summit on ethical and pol...e medical community while preparing for a large-sc...Health, the Indiana University Center for Bioethic...
...Bipartisan Bill Improves Low-Income Help and Boost...Helps Ensure Access to Doctors, NEW YORK, July 15... and Senate voted overwhelmingly to override a,Whi...grams, boost health care quality with a system of ...
...OPTOMETRISTS LEAD WINNING PATIENT ACCESS COALITION...sociation (AOA) applauds Members of Congress from ...,s veto of legislation passed to stop massive,cuts... safeguard patient,access to eye and vision care t...
Other Medicine News:Health News:Robert E Cook Honors College Women In Medicine 2Health News:Robert E Cook Honors College Women In Medicine 3Health News:Robert E Cook Honors College Women In Medicine 4Health News:Robert E Cook Honors College Women In Medicine 5Health News:Robert E Cook Honors College Women In Medicine 6Health News:Orion Health's Dr. Chris Hobson Selected to Speak at World Congress Public Health Conference 2Health News:Orion Health's Dr. Chris Hobson Selected to Speak at World Congress Public Health Conference 3Health News:Medical And Nursing Scrubs Retailer Blue Sky Scrubs Unveils New Website 2Health News:Confronting Ethics of Pandemic Influenza Planning: 2008 Summit of the States 2Health News:AARP NY Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 2Health News:AARP NY Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 3Health News:American Optometric Association Applauds Override of Medicare Cuts 2Health News:American Optometric Association Applauds Override of Medicare Cuts 3
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: